Search | Clinical Trials Finder

Conditions: Cognitive Impairment, Elderly
Interventions: 2g Centella asiatica water extract product, 4g Centella asiatica water extract product; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Severe Hemophilia A, Moderate Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 69 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • Oklahoma City, Oklahoma

Conditions: Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Interventions: Nanvuranlat, Physician's Best Choice; Drug · Other
Lead sponsor: J-Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Duarte, California • Orange, California • Santa Monica, California + 15 more

Conditions: Healthy
Interventions: MK-1167, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions: RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 60 Years and older
Enrollment: 646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more

Conditions: Congenital Erythropoietic Porphyria (CEP)
Interventions: ATL-001 (Ciclopirox oral solution); Drug
Lead sponsor: Atlas Molecular Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Alzheimers Disease
Interventions: CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more

Conditions: Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
Interventions: Asundexian (BAY2433334), Apixaban, Asundexian matching placebo, Apixaban matching placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14,830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 163
States / cities: Dothan, Alabama • Fairhope, Alabama • Mobile, Alabama + 144 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BIIB017 (peginterferon beta-1a), Interferon beta type 1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia

Conditions: Influenza A Virus
Interventions: JNJ-63623872, Placebo, Oseltamivir; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Fresno, California • Long Beach, California • Stanford, California + 11 more

Conditions: Focal Seizures
Interventions: CBD-OS; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more

Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
Interventions: Ad26.COV2.S, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 31,835 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 63
States / cities: Vestavia Hills, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Elderly Study Participants, Adult Study Participants
Interventions: Padsevonil; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 28
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Dimethyl Fumarate, Peginterferon Beta-1a, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
Interventions: Placebo, Lemborexant 10 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Glendale, Arizona • San Diego, California • Brandon, Florida + 7 more

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more

Conditions: HCV Infection
Interventions: EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules, Elbasvir Oral Granules; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions: Decitabine, Laboratory Biomarker Analysis, Venetoclax; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colitis Ulcerative
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 27
States / cities: Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more

Conditions: Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
Interventions: Asundexian (BAY2433334), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 12,327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 108
States / cities: Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Gingivitis, Gingival Bleeding, Dental Plaque
Interventions: Electric Flosser, Manual Toothbrush; Device
Lead sponsor: Flaus, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Interventions: Ad26.COV2.S, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 44,325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 117
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more

Search by objective public record fields.

Pharmacokinetics Centella Asiatica Product (CAP) in Mild Cognitive Impairment

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Safety and Efficacy of Flaus Electric Flosser on Plaque and Gingivitis Compared to a Manual Toothbrush

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants